Apply to trial NCT05310643

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 2Drug trial

Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC

NIPIRESCUE evaluates nivolumab and ipilimumab in patients with MSI/dMMR mCRC resistant to anti-PD1 monotherapy and previously treated with fluoropyrimidine, oxaliplatine, irinotecan, and anti- vascular endothelial growth factor (VEGF) or anti- epidermal growth factor receptor (EGFR) therapy.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening